Less than 10% of patients that would benefit from weight-loss injections including Wegovy are able to get them, states the World Health Organization as it issues its first guidance on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging more widespread and fairer access to GLP-1 medication.
According to forecasts, over two billion could be living with obesity by 2030 without intervention.
"Our latest guidance acknowledges that excess weight is a long-term condition that can be treated with holistic and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major obstacles to widespread availability to the treatments that can aid individuals in losing significant weight, says the organization.
Skinny Jab Supply Crisis
Even in the current best projected outlook, the manufacturing of such drugs would only suffice for approximately 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline encourages countries and companies to expand access, via measures such as licensing agreements.
The intellectual property rights on semaglutide – the primary component of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs imitate a natural hormone to reduce digestion speed, curb appetite and boost satiety so individuals reduce food intake.
People commonly start to lose weight within a few weeks of starting on the regular doses.
Studies indicates people may see weight return a year later of stopping the drug, when their normal food cravings resume.
Being above a healthy weight raises your risk for contracting diseases, like type 2 diabetes, heart disease, stroke, and some malignancies.
Obesity concerns people in all nations and was associated with over three and a half million fatalities worldwide in 2024, as per the health agency.
